Although sorafenib is not currently included in the standard treatment of CCA, in vitro studies have demonstrated that the uptake of other drugs, such as platinum derivatives used in first-line pharmacological regimes, is affected by the appearance of inactivating variants of OCT1[85]. This evidence concerns the gene SLC22A1 and cholangiocarcinoma.